TEST:

PanCanSeek®

"SeekIn Inc...today announced it has received authorization for five U.S. trademarks, further expanding its robust global intellectual property portfolio. The newly registered trademarks—SeekInCare® (blood-based pan-cancer early detection test), OncoSeek® (blood-based, low-cost multi-cancer early detection test), SeekInClarity® (blood-based pan-cancer treatment response monitoring test), LeukoPrint® (molecular karyotyping test for hematologic malignancies), and PanCanSeek® (precision diagnosis and therapeutic guidance for hematologic malignancies)—mark a significant milestone following successful trademark registrations in China and the European Union."

"SeekIn Inc...announced that it has obtained authorization to use five trademarks within the United States, including SeekInCare® (blood-based pan-cancer early detection test), OncoSeek® (blood-based low-cost multi-cancer early detection test), SeekInClarity® (blood-based pan-cancer treatment response monitoring test), LeukoPrint® (hematologic malignancies molecular karyotyping test), and PanCanSeek® (hematologic malignancies precision diagnosis and therapeutics guidance test). These acquisitions strengthen SeekIn Inc.'s intellectual property portfolio and open new avenues for the company to expand its reach and enhance its services within the United States."

"SeekIn Inc...announced today that it has obtained authorization to use eight trademarks within the European Union, including SeekInCare (the first-in-class blood-based pan-cancer early detection test), SeekInCure (the first-in-class blood-based pan-cancer recurrence monitoring test), SeekInClarity (pan-cancer treatment response monitoring), OncoSeek (low-cost early cancer detection test), LungCanSeek (lung cancer early detection test), LeukoPrint (the first-in-class leukemia sWGS CNA test), PanCanSeek (pan-cancer therapy guidance test)..."

"SeekIn Inc...announced CE (Conformité Européenne) Mark approval for PanCanSeek® Cancer Mutation Detection Kit and is now ready to launch this test in European Union and other countries that recognize CE-IVD Mark...PanCanSeek® is developed as the world's first integrated solution for leukemia cytogenetics and molecular diagnostics. It uses high-depth WGS, which can cover four different detection techniques – karyotyping for CNV, FISH for gene fusion, qPCR for single mutation and targeted NGS panel for multiple mutations."